Viral Hemorrhagic Fevers

Clinics in Laboratory Medicine

Volumn 26, Issue 2, 2006, Pages 345-386

  Marty, Aileen M ^a   Jahrling, Peter B ^b   Geisbert, Thomas W ^c  

^a BATTELLE MEMORIAL INSTITUTE   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTISERUM; ANTIVIRUS AGENT; BETA INTERFERON; CHEMOKINE; CYTOKINE; FIBRIN DEGRADATION PRODUCT; FIBRINOGEN; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERFERON; INTERFERON REGULATORY FACTOR 3; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; NUCLEOSIDE DERIVATIVE; PROTHROMBIN; RANTES; REACTIVE OXYGEN METABOLITE; RIBAVIRIN; TUMOR NECROSIS FACTOR ALPHA; VIRUS GLYCOPROTEIN; VIRUS VACCINE;

ADULT RESPIRATORY DISTRESS SYNDROME; AFRICA; ANTIVIRAL ACTIVITY; ARENAVIRUS; ARGENTINE HEMORRHAGIC FEVER; ASIA; BIOLOGICAL WARFARE; BLOOD CLOTTING DISORDER; BOLIVIAN HEMORRHAGIC FEVER; BRAZILIAN HEMORRHAGIC FEVER; BUNYAVIRUS; CLINICAL EXAMINATION; CLINICAL FEATURE; CRIMEAN CONGO HEMORRHAGIC FEVER; DENGUE; DIAGNOSTIC PROCEDURE; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG APPROVAL; EGYPT; ENZYME LINKED IMMUNOSORBENT ASSAY; EUROPE; EXPERIMENTAL ANIMAL; EXPERIMENTAL MOUSE; EXPERIMENTAL RAT; FILOVIRIDAE; FLAVIVIRUS; FOOD AND DRUG ADMINISTRATION; GEOGRAPHIC DISTRIBUTION; HANTAVIRUS; HEMORRHAGIC FEVER; HOSPITAL INFECTION; HUMAN; IMMUNE DEFICIENCY; IMMUNIZATION; IMMUNOCYTOCHEMISTRY; IMMUNOGENICITY; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; JUNIN VIRUS; LASSA FEVER; LASSA VIRUS; MARBURG HEMORRHAGIC FEVER; MOLECULAR PHYLOGENY; MONKEY; NONHUMAN; OMSK HEMORRHAGIC FEVER; PALLIATIVE THERAPY; PARTIAL THROMBOPLASTIN TIME; PASSIVE IMMUNIZATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTHROMBIN TIME; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SAUDI ARABIA; THROMBOCYTOPENIA; TREATMENT INDICATION; UNITED STATES; VENEZUELAN HEMORRHAGIC FEVER; VESICULAR STOMATITIS VIRUS; VIRUS EXAMINATION; VIRUS HEMORRHAGIC FEVER; VIRUS INFECTION; VIRUS PATHOGENESIS; VIRUS REPLICATION; VIRUS TRANSMISSION; VIRUS VIRULENCE; YELLOW FEVER; YEMEN;

ANIMALS; BIOTERRORISM; HEMORRHAGIC FEVERS, VIRAL; HUMANS;

EID: 33745405002     PISSN: 02722712     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cll.2006.05.001     Document Type: Review

References (283)

1. McKay D.G., and Margaretten W. Disseminated intravascular coagulation in virus diseases. Arch Intern Med 120 (1967) 129-152
2. Lee H.W. Hemorrhagic fever with renal syndrome in Korea. Rev Infect Dis 11 Suppl 4 (1989) S864-S876
3. Canonico P.G., Kende M., Luscri B.J., et al. In-vivo activity of antivirals against exotic RNA viral infections. J Antimicrob Chemother 14 Suppl A (1984) 27-41
4. McCormick J.B., King I.J., Webb P.A., et al. Lassa fever. Effective therapy with ribavirin. N Engl J Med 314 (1986) 20-26
5. Huggins J.W., Hsiang C.M., Cosgriff T.M., et al. Prospective, double-blind, concurrent, placebo-controlled clinical trial of intravenous ribavirin therapy of hemorrhagic fever with renal syndrome. J Infect Dis 164 (1991) 1119-1127
6. Barry M., Russi M., Armstrong L., et al. Brief report: treatment of a laboratory-acquired Sabia virus infection. N Engl J Med 333 (1995) 294-296
7. Enria D.A., Briggiler A.M., Levis S., et al. Tolerance and antiviral effect of ribavirin in patients with Argentine hemorrhagic fever. Antiviral Res 7 (1987) 353-359
8. Huggins J.W. Prospects for treatment of viral hemorrhagic fevers with ribavirin, a broad-spectrum antiviral drug. Rev Infect Dis 11 Suppl 4 (1989) S750-S761
9. Kilgore P.E., Ksiazek T.G., Rollin P.E., et al. Treatment of Bolivian hemorrhagic fever with intravenous ribavirin. Clin Infect Dis 24 (1997) 718-722
10. Fisher-Hoch S.P., Khan J.A., Rehman S., et al. Crimean Congo-haemorrhagic fever treated with oral ribavirin. Lancet 346 (1995) 472-475
11. Mardani M., Jahromi M.K., Naieni K.H., et al. The efficacy of oral ribavirin in the treatment of crimean-congo hemorrhagic fever in Iran. Clin Infect Dis 36 (2003) 1613-1618
12. Ergonul O., Celikbas A., Dokuzoguz B., et al. Characteristics of patients with Crimean-Congo hemorrhagic fever in a recent outbreak in Turkey and impact of oral ribavirin therapy. Clin Infect Dis 39 (2004) 284-287
13. Sbrana E., Xiao S.Y., Guzman H., et al. Efficacy of post-exposure treatment of yellow fever with ribavirin in a hamster model of the disease. Am J Trop Med Hyg 71 (2004) 306-312
14. Ignat'ev G.M., Strel'tsova M.A., Agafonov A.P., et al. Experimental study of possible treatment of Marburg hemorrhagic fever with desferal, ribavirin, and homologous interferon. Vopr Virusol 41 (1996) 206-209
15. Jahrling P.B., Geisbert T.W., Geisbert J.B., et al. Evaluation of immune globulin and recombinant interferon-alpha2b for treatment of experimental Ebola virus infections. J Infect Dis 179 Suppl 1 (1999) S224-S234
16. Kolokol'tsov A.A., Davidovich I.A., Strel'tsova M.A., et al. The use of interferon for emergency prophylaxis of Marburg hemorrhagic fever in monkeys. Bull Exp Biol Med 132 (2001) 686-688
17. Morrill J.C., Jennings G.B., Cosgriff T.M., et al. Prevention of Rift Valley fever in rhesus monkeys with interferon-α. Rev Infect Dis 11 Suppl 4 (1989) S815-S825
18. Morrill J.C., Czarniecki C.W., and Peters C.J. Recombinant human interferon-gamma modulates Rift Valley fever virus infection in the rhesus monkey. J Interferon Res 11 (1991) 297-304
19. Stille W., Bohle E., Helm E., et al. Uber eine durch Cercopithecus aethiops ubertragene Infektionskrankheit. ("Grune-Meerkatzen-Krankheit", "Green Monkey Disease") (German). [On an infectious disease transmitted by Cercopithecus aethiops ("Green monkey disease")]. Dtsch Med Wochenschr 93 (1968) 572-582
20. Leifer E., Gocke D.J., and Bourne H. Lassa fever, a new virus disease in man from West Africa, II: report of a laboratory-acquired infection treated with plasma from a person recently recovered from the disease. Am J Trop Med Hyg 19 (1970) 677-679
21. White H.A. Lassa fever: a study of 23 hospital cases. Trans R Soc Trop Med Hyg 66 (1972) 390-401
22. Monath T.P., Maher M., Casals J., et al. Lassa fever in the Eastern Province of Sierra Leone, 1970-1972, II: clinical observations and virological studies on selected hospital cases. Am J Trop Med Hyg 23 (1974) 1140-1149
23. Clayton A.J. Lassa immune serum. Bull World Health Organ 55 (1977) 435-439
24. Emond R.T., Evans B., Bowen E.T., et al. A case of Ebola virus infection. BMJ 2 (1977) 541-544
25. Maiztegui J.I., Fernandez N.J., and de Damilano A.J. Efficacy of immune plasma in treatment of Argentine haemorrhagic fever and association between treatment and a late neurological syndrome. Lancet 2 (1979) 1216-1217
26. Enria D.A., Fernandez N.J., Briggiler A.M., et al. Importance of neutralizing antibodies in treatment of Argentine hemorrhagic fever with immune plasma. Lancet 4 (1984) 255-256
27. Frame J.D., Verbrugge G.P., Gill R.G., et al. The use of Lassa fever convalescent plasma in Nigeria. Trans R Soc Trop Med Hyg 78 (1984) 319-324
28. Mupapa K., Massamba M., Kibadi K., et al. Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. J Infect Dis 179 Suppl 1 (1999) S18-S23
29. Sadek R.F., Khan A.S., Stevens G., et al. Ebola hemorrhagic fever, Democratic Republic of the Congo, 1995: determinants of survival. J Infect Dis 179 Suppl 1 (1999) S24-S27
30. Alibek K., and Handelman S. Biohazard: The Chilling True Story of the Largest Covert Biological Weapons Program in the World. Told From the Inside by the Man Who Ran It (1999), Random House, New York
31. Center for Nonproliferation Studies. Chemical and biological weapons: possession and programs past and present. November 2000. Available at: http://cns.miis.edu/research/cbw/possess.htm Accessed June 4, 2006.
32. Miller J., Engelberg S., and Broad W.J. Germs: Biological Weapons and America's Secret War (2001), Simon & Schuster, Waterville, ME
33. Monath T.P. Yellow fever vaccine. Expert Rev Vaccines 4 (2005) 553-574
34. McKee Jr. K.T., Oro J.G., Kuehne A.I., et al. Candid No. 1 Argentine hemorrhagic fever vaccine protects against lethal Junin virus challenge in rhesus macaques. Intervirology 34 (1992) 154-163
35. Maiztegui J.I., McKee Jr. K.T., Barrera Oro J.G., et al. Protective efficacy of a live attenuated vaccine against Argentine hemorrhagic fever. J Infect Dis 177 (1998) 277-283
36. Pittman P.R., Liu C.T., Cannon T.L., et al. Immunogenicity of an inactivated Rift Valley fever vaccine in humans. Vaccine 18 (1999) 181-189
37. Hooper J.W., and Li D. Vaccines against hantaviruses. Curr Top Microbiol Immunol 256 (2001) 171-191
38. Sullivan N.J., Sanchez A., Rollin P.E., et al. Development of a preventive vaccine for Ebola virus infection in primates. Nature 408 (2000) 605-609
39. Sullivan N.J., Geisbert T.W., Geisbert J.B., et al. Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature 424 (2003) 681-684
40. Sullivan N.J., Geisbert T.W., Geisbert J.B., et al. Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs. PLoS Med 3 6 (2006) e177
41. Jones S.M., Feldmann H., Stroher U., et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med Jun (2005) 5 [Epub ahead of print]
42. Geisbert T.W., Jones S., Fritz E.A., et al. Development of a new vaccine for the prevention of Lassa fever. PLoS Med (2005) Jun;2(6):e183. Epub 2005 Jun 28
43. Daddario-DiCaprio K.M., Geisbert T.W., Stroher U., et al. Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessment. Lancet 367 (2006) 1399-1404
44. Warfield K.L., Bosio C.M., Welcher B.C., et al. Ebola virus-like particles protect from lethal Ebola virus infection. Proc Natl Acad Sci USA 100 (2003) 15889-15894
45. Hevey M., Negley D., Pushko P., et al. Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates. Virology 251 (1998) 28-37
46. Geisbert T.W., Pushko P., Anderson K., et al. Evaluation in nonhuman primates of vaccines against Ebola virus. Emerg Infect Dis 8 (2002) 503-507
47. Bowen M.D., Peters C.J., and Nichol S.T. The phylogeny of New World (Tacaribe complex) arenaviruses. Virology 219 (1996) 285-290
48. McCormick J.B., Webb P.A., Krebbs J.W., et al. A prospective study of epidemiology and ecology of Lassa fever. J Infect Dis 155 (1987) 437-444
49. Birmingham K., and Kenyon G. Lassa fever is unheralded problem in West Africa. Nat Med 7 (2001) 878
50. Freedman D.O., and Woodall J. Emerging infectious diseases and risk to the traveler. Med Clin North Am 83 (1999) 865-883
51. Schmitz H., Kohler B., Laue T., et al. Monitoring of clinical and laboratory data in two cases of imported Lassa fever. Microbes Infect 4 (2002) 43-50
52. Centers for Disease Control and Prevention (CDC). Imported Lassa fever - New Jersey, 2004. MMWR Morb Mortal Wkly Rep 53 (2004) 894-897
53. Maiztegui J., Feuillade M., and Briggiler A. Progessive extension of the endemic area and changing incidence of Argentine hemorrhagic fever. Med Microbiol Immunol (Berl) 175 (1986) 149-152
54. Johnson K.M., Wiebenga N.H., Mackenzie R.B., et al. Virus isolations from human cases of hemorrhagic fever in Bolivia. Proc Soc Exp Biol Med 118 (1965) 113-118
55. Salas R., de Manzione N., Tesh R.B., et al. Venezuelan haemorrhagic fever. Lancet 338 (1991) 1033-1036
56. Lisieux T., Coimbra M., Nassar E.S., et al. New arenavirus isolated in Brazil. Lancet 343 (1994) 391-392
57. Centers for Disease Control and Prevention. Fatal illness associated with a new world arenavirus-California. MMWR Morb Mortal Wkly Rep 49 (2000) 709-711
58. Buchmeier M.J., Bowen M.D., and Peters C.J. Arenaviridae: the viruses and their replication. In: Fields B.N., Knipe D.M., Howley P.M., et al. (Eds). Fields Virology (2001), Lippincott Williams & Wilkins, Philadelphia 1635-1668
59. Bowen M.D., Peters C.J., and Nichol S.T. The phylogeny of New World (Tacaribe complex) arenaviruses. Virology 219 (1996) 285-290
60. Strecker T., Eichler R., Meulen J., et al. Lassa virus Z protein is a matrix protein and sufficient for the release of virus-like particles. J Virol 77 (2003) 10700-10705
61. Buchmeier M.J., Southern P.J., Parekh B.S., et al. Site-specific antibodies define a cleavage site conserved among arenavirus GP-C glycoproteins. J Virol 61 (1987) 982-985
62. Buchmeier M.J., Lewicki H.A., Tomori O., et al. Monoclonal antibodies to lymphocytic choriomeningitis and pichinde viruses: generation, characterization, and cross-reactivity with other arenaviruses. Virology 113 (1981) 73-85
63. Bruns M., Cihak J., Muller G., et al. Lymphocytic choriomeningitis virus. VI. Isolation of a glycoprotein mediating neutralization. Virology 130 (1983) 247-251
64. Glushakova S.E., Lukashevich I.S., and Baratova L.A. Prediction of arenavirus fusion peptides on the basis of computer analysis of envelope protein sequences. FEBS Lett 269 (1990) 145-147
65. Di Simone C., Zandonatti M.A., and Buchmeier M.J. Acidic pH triggers the LCMV membrane fusion activity and conformational change in the glycoprotein spike. Virology 198 (1994) 455-465
66. Daubney R., Hudson J.R., and Garnham P.C. Enzootic hepatitis or Rift valley fever. An undescribed virus disease of sheep, cattle and man from East Africa. J Pathol Bacteriol 34 (1931) 545-579
67. Easterday B.C. Rift Valley fever. Adv Vet Sci 10 (1965) 65-127
68. Shawky S. Rift Valley fever. Saudi Med J 21 (2000) 1109-1115
69. Collaborating WHO. Centre for Research and Training in Veterinary Epidemiology and Management. Report of the WHO/IZSTE Consultation on Recent Developments in Rift Valley Fever (RVF) (With the Participation of FAO and OIE).1993;128:1-23. Civitella del Tronto, Italy; 14-15 September 1993. WHO/CDS/VPH/93.123.
70. van Eeden P.J., van Eeden S.F., Joubert J.R., et al. A nosocomial outbreak of Crimean-Congo haemorrhagic fever at Tygerberg Hospital, II: Management of patients. S Afr Med J 68 (1985) 718-721
71. Nuzum E.O., Rossi C.A., Stephenson E.H., et al. Aerosol transmission of Hantaan and related viruses to laboratory rats. Am J Trop Med Hyg 38 (1988) 636-640
72. Lee H.W. Hemorrhagic fever with renal syndrome in Korea. Rev Infect Dis 11 Suppl 4 (1989) S864-S876
73. Butler J.C., and Peters C.J. Hantaviruses and Hantavirus Pulmonary Syndrome. Clin Infect Dis 19 (1994) 387-395
74. Peters C.J., and Khan A.S. Hantavirus pulmonary syndrome: the new American hemorrhagic fever. Clin Infect Dis 34 (2002) 1224-1231
75. Elliott R.M. Molecular biology of the Bunyaviridae. J Gen Virol 71 (1990) 501-522
76. Bouloy M. Bunyaviridae: genome organization and replication strategies. Adv Virus Res 40 (1991) 235-275
77. Schmaljohn C.S., and Hooper J.W. Bunyaviridae: The Viruses and Their Replication. In: Fields B.N., Knipe D.M., Howley P.M., et al. (Eds). Fields Virology (2001), Lippincott Williams & Wilkins, Philadelphia 1581-1602
78. Weber F., Bridgen A., Fazakerley J.K., et al. Bunyamwera bunyavirus nonstructural protein NSs counteracts the induction of alpha/beta interferon. J Virol 76 (2002) 7949-7955
79. Martini G.A. Marburg virus disease. Clinical syndrome. In: Martini G.A., and Siegert R. (Eds). Marburg Virus Disease (1971), Springer-Verlag, New York 1-9
80. Zeller H. Les leçons de l'épidémie a virus Marburg a Durba, République Démocratique du Congo (1998-2000). [French]. [Lessons from the Marburg virus epidemic in Durba, Democratic Republic of the Congo (1998-2000)]. Med Trop (Mars) 60 Suppl (2000) 23-26
81. Centers for Disease Control and Prevention (CDC). Outbreak of Marburg virus hemorrhagic fever-Angola, October 1, 2004-March 29, 2005. MMWR Morb Mortal Wkly Rep 54 (2005) 308-309
82. World Health Organization International Study Team. Ebola haemorrhagic fever in Zaire, 1976. Bull World Health Organ 56 (1978) 271-293
83. World Health Organization International Study Team. Ebola haemorrhagic fever in Sudan, 1976. Bull World Health Organ 56 (1978) 247-270
84. Khan A.S., Tshioko F.K., Heymann D.L., et al. The reemergence of Ebola hemorrhagic fever, Democratic Republic of the Congo, 1995. J Infect Dis 179 Suppl 1 (1995) S76-S86
85. Georges-Courbot M.C., Sanchez A., Lu C.Y., et al. Isolation and phylogenetic characterization of Ebola viruses causing different outbreaks in Gabon. Emerg Infect Dis 3 (1997) 59-62
86. Centers for Disease Control and Prevention. Outbreak of Ebola hemorrhagic fever Uganda, August 2000-January 2001. MMWR Morb Mortal Wkly Rep 50 (2001) 73-77
87. Walsh P.D., Abernethy K.A., Bermejo M., et al. Catastrophic ape decline in western equatorial Africa. Nature 422 (2003) 611-614
88. Rouquet P., Froment J.M., Bermejo M., et al. Wild animal mortality monitoring and human Ebola outbreaks, Gabon and Republic of Congo, 2001-2003. Emerg Infect Dis 11 (2005) 283-290
89. Jahrling P.B., Geisbert T.W., Dalgard D.W., et al. Preliminary report: isolation of Ebola virus from monkeys imported to the USA. Lancet 335 (1990) 502-505
90. Le Guenno B., Formentry P., Wyers M., et al. Isolation and partial characterisation of a new strain of Ebola virus. Lancet 345 (1995) 1271-1274
91. Swanepoel R., Leman P.A., Burt F.J., et al. Experimental inoculation of plants and animals with Ebola virus. Emerg Infect Dis 2 (1996) 321-325
92. Leroy E.M., Kumulungui B., Pourrut X., et al. Fruit bats as reservoirs of Ebola virus. Nature 438 (2005) 575-576
93. Sanchez A., Kiley M.P., Holloway B.P., et al. Sequence analysis of the Ebola virus genome: organization, genetic elements, and comparison with the genome of Marburg virus. Virus Res 29 (1993) 215-240
94. Sanchez A., Khan A.S., Zaki S.R., et al. Filoviridae: Marburg and Ebola viruses. In: Fields B.N., Knipe D.M., Howley P.M., et al. (Eds). Fields Virology (2001), Lippincott Williams & Wilkins, Philadelphia
95. Takada A., Robison C., Goto H., et al. A system for functional analysis of Ebola virus glycoprotein. Proc Natl Acad Sci USA 94 (1997) 14764-14769
96. Ito H., Watanabe S., Sanchez A., et al. Mutational analysis of the putative fusion domain of the Ebola virus glycoprotein. J Virol 73 (1999) 8907-8912
97. Sanchez A., Yang Z.Y., Xu L., et al. Biochemical analysis of the secreted and virion glycoproteins of Ebola virus. J Virol 72 (1998) 6442-6447
98. Volchkov V.E., Feldmann H., Volchkova V.A., et al. Processing of the Ebola virus glycoprotein by the proprotein convertase furin. Proc Natl Acad Sci USA 95 (1998) 5762-5767
99. Volchkov V.E., Becker S., Volchkova V.A., et al. GP mRNA of Ebola virus is edited by the Ebola virus polymerase and by T7 and vaccinia virus polymerases. Virology 214 (1995) 421-430
100. Sanchez A., Trappier S.G., Mahy B.W., et al. The virion glycoproteins of Ebola viruses are encoded in two reading frames and are expressed through transcriptional editing. Proc Natl Acad Sci USA 93 (1996) 3602-3607
101. Noda T., Sagara H., Suzuki E., et al. Ebola virus VP40 drives the formation of virus-like filamentous particles along with GP. J Virol 76 (2002) 4855-4865
102. Han Z., Boshra H., Sunyer J.O., et al. Biochemical and functional characterization of the Ebola virus VP24 protein: implications for a role in virus assembly and budding. J Virol 77 (2003) 1793-1800
103. Monath T.P. Yellow fever: Victor Victoria? Conqueror, conquest? Epidemics and research in the last forty years and prospects for the future. Am J Trop Med Hyg 45 (1991) 1-43
104. Halstead S.B. Antibody, macrophages, dengue virus infection, shock, and hemorrhage: a pathogenetic cascade. Rev Infect Dis 11 Suppl 4 (1989) S830-S839
105. Rosen L. Disease exacerbation caused by sequential dengue infections: myth or reality?. Rev Infect Dis 11 Suppl 4 (1989) S840-S842
106. Kurane I., and Takasaki T. Dengue fever and dengue haemorrhagic fever: challenges of controlling an enemy still at large. Rev Med Virol 11 (2001) 301-311
107. Lei H.Y., Yeh T.M., Liu H.S., et al. Immunopathogenesis of dengue virus infection. J Biomed Sci 8 (2001) 377-388
108. Guzman M.G., and Kouri G. Dengue: an update. Lancet Infect Dis 2 (2002) 33-42
109. Pavri K. Clinical, clinicopathological, and hematologic features of Kyasanur Forest disease. Rev Infect Dis 11 Suppl 4 (1989) S854-S859
110. Chumakov M.P. (1959) Studies of virus hemorrhagic fevers. J Hyg Epidemiol Microbiol Immunol 7 (1959) 125-135
111. Charrel R.N., Zaki A.M., Attoui H., et al. Complete coding sequence of the Alkhurma virus, a tick-borne flavivirus causing severe hemorrhagic fever in humans in Saudi Arabia. Biochem Biophys Res Commun 287 (2001) 455-461
112. Chambers T.J., Hahn C.S., Galler R., et al. Flavivirus genome organization, expression, and replication. Annu Rev Microbiol 44 (1990) 649-688
113. Lindenbach B.D., and Rice C.M. Flaviviridae: The viruses and their replication. In: Fields B.N., Knipe D.M., Howley P.M., et al. (Eds). Fields Virology (2001), Lippincott Williams & Wilkins, Philadelphia 991-1041
114. Mackenzie J.M., Jones M.K., and Young P.R. Immunolocalization of the dengue virus nonstructural glycoprotein NS1 suggests a role in viral RNA replication. Virology 220 (1996) 232-240
115. Mackenzie J.M., Khromykh A.A., Jones M.K., et al. Subcellular localization and some biochemical properties of the flavivirus Kunjin nonstructural proteins NS2A and NS4A. Virology 245 (1998) 203-215
116. Liu W.J., Chen H.B., Wang X.J., et al. Analysis of adaptive mutations in Kunjin virus replicon RNA reveals a novel role for the flavivirus nonstructural protein NS2A in inhibition of beta interferon promoter-driven transcription. J Virol 78 (2004) 12225-12235
117. Clum S., Ebner K.E., and Padmanabhan R. Cotranslational membrane insertion of the serine proteinase precursor NS2B-NS3(Pro) of dengue virus type 2 is required for efficient in vitro processing and is mediated through the hydrophobic regions of NS2B. J Biol Chem 272 (1997) 30715-30723
118. Gorbalenya A.E., Donchenko A.P., Koonin E.V., et al. N-terminal domains of putative helicases of flavi- and pestiviruses may be serine proteases. Nucleic Acids Res 17 (1989) 3889-3897
119. Preugschat F., Yao C.W., and Strauss J.H. In vitro processing of dengue virus type 2 nonstructural proteins NS2A, NS2B, and NS3. J Virol 64 (1990) 4364-4374
120. Arias C.F., Preugschat F., and Strauss J.H. Dengue 2 virus NS2B and NS3 form a stable complex that can cleave NS3 within the helicase domain. Virology 193 (1993) 888-899
121. Failla C., Tomei L., and De Francesco R. Both NS3 and NS4A are required for proteolytic processing of hepatitis C virus nonstructural proteins. J Virol 68 (1994) 3753-3760
122. Lin C., Wu J.W., Hsiao K., et al. The hepatitis C virus NS4A protein: interactions with the NS4B and NS5A proteins. J Virol 71 (1997) 6465-6471
123. Munoz-Jordan J.L., Sanchez-Burgos G.G., Laurent-Rolle M., et al. Inhibition of interferon signaling by dengue virus. Proc Natl Acad Sci USA 100 (2003) 14333-14338
124. Koonin E.V. Computer-assisted identification of a putative methyltransferase domain in NS5 protein of flaviviruses and lambda 2 protein of reovirus. J Gen Virol 74 (1993) 733-740
125. Tan B.H., Fu J., Sugrue R.J., et al. Recombinant dengue type 1 virus NS5 protein expressed in Escherichia coli exhibits RNA-dependent RNA polymerase activity. Virology 216 (1996) 317-325
126. Centers for Disease Control and Prevention. Category A agents. Available at: http://www.bt.cdc.gov/Agent/agentlist.asp. Accessed June 4, 2006.
127. Williams P., and Wallace D. Unit 731, Japan's Secret Biological Warfare in World War II (1989), The Free Press, New York 38-40
128. P'yankov O.V., Sergeev A.N., P'yankova O.G., et al. Experimental Ebola fever in macaca rhesus. [Russian]. Vopr Virusol 40 (1995) 113-115
129. Johnson E., Jaax N., White J., et al. Lethal experimental infections of rhesus monkeys by aerosolized Ebola virus. Int J Exp Pathol 76 (1995) 227-236
130. Bazhutin N.B., Belanov E.F., Spiridonov V.A., et al. The effect of the methods for producing an experimental Marburg virus infection on the characteristics of the course of the disease in green monkeys. [Russian]. Vopr Virusol 37 (1992) 153-156
131. Lub M. Iu, Sergeev AN, P'iankov OV, et al. Certain pathogenetic characteristics of a disease in monkeys infected with the Marburg virus by an airborne route [Russian]. Vopr Virusol 1995;40:158-61.
132. Stephenson E.H., Larsen E.W., and Dominik J.W. Effect of environmental factors on aerosol-induced Lassa virus infection. J Med Virol 14 (1984) 295-303
133. Kenyon R.H., McKee Jr. K.T., Zack P.M., et al. Aerosol infection of rhesus macaques with Junin virus. Intervirology 33 (1992) 23-31
134. nd Session (1996). Available at: http://www.fas.org/irp/congress/1995_rpt/aum/part05.htm. Accessed on June 4, 2006.
135. Federation of American Scientists. Chemical and Biological Arms Control Program. Weapons of Mass Destruction Around the World. Report on North Korea. Biological Systems. Available at: http://www.fas.org/nuke/guide/dprk/bw/index.html. Accessed June 4, 2006.
136. World Health Organization Group of Consultants. Health aspects of chemical and biologic weapons (1970), World Health Organization, Geneva 98-109
137. Borio L., Inglesby T., Peters C.J., et al. Hemorrhagic fever viruses as biological weapons. JAMA 287 (2002) 2391-2405
138. Peters C.J., Jahrling P.B., and Khan A.S. Patients infected with high-hazard viruses. Arch Virol 11 Suppl (1996) 141-168
139. Maiztegui J.I., Laguens R.P., Cossio P.M., et al. Ultrastructural and immunohistochemical studies in five cases of Argentine hemorrhagic fever. J Infect Dis 132 (1975) 35-53
140. Gonzalez P.H., Cossio P.M., Arana R., et al. Lymphatic tissue in Argentine hemorrhagic fever. Pathologic features. Arch Pathol Lab Med 104 (1980) 250-254
141. Jahrling P.B., Hesse R.A., Eddy G.A., et al. Lassa virus infection of rhesus monkeys: pathogenesis and treatment with ribavirin. J Infect Dis 141 (1980) 580-589
142. De Brito T., Siqueira S.A., Santos R.T., et al. Human fatal yellow fever. Immunohistochemical detection of viral antigens in the liver, kidney and heart. Pathol Res Pract 188 (1992) 177-181
143. Geisbert T.W., Jahrling P.B., Hanes M.A., et al. Association of Ebola-related Reston virus particles and antigen with tissue lesions of monkeys imported to the United States. J Comp Pathol 106 (1992) 137-152
144. Zaki S.R., Greer P.W., Coffield L.M., et al. Hantavirus pulmonary syndrome. Pathogenesis of an emerging infectious disease. Am J Pathol 46 (1995) 552-579
145. Jaax N.K., Davis K.J., Geisbert T.W., et al. Lethal experimental infection of rhesus monkeys with Ebola-Zaire (Mayinga) virus by the oral and conjunctival route of exposure. Arch Pathol Lab Med 120 (1996) 140-155
146. Burt F.J., Swanepoel R., Shieh W.J., et al. Immunohistochemical and in situ localization of Crimean-Congo hemorrhagic fever (CCHF) virus in human tissues and implications for CCHF pathogenesis. Arch Pathol Lab Med 121 (1997) 839-846
147. Geisbert T.W., and Jaax N.K. Marburg hemorrhagic fever: report of a case studied by immunohistochemistry and electron microscopy. Ultrastr Pathol 22 (1998) 3-17
148. Zaki S.R., and Goldsmith C.S. Pathologic features of filovirus infections in humans. Curr Top Microbiol Immunol 235 (1999) 97-116
149. de Filippis A.M., Nogueira R.M., Schatzmayr H.G., et al. Outbreak of jaundice and hemorrhagic fever in the Southeast of Brazil in 2001: detection and molecular characterization of yellow fever virus. J Med Virol 68 (2002) 620-627
150. Geisbert T.W., Hensley L.E., Larsen T., et al. Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection. Am J Pathol 163 (2003) 2347-2370
151. Geisbert T.W., Young H.A., Jahrling P.B., et al. Pathogenesis of Ebola hemorrhagic fever in primate models: evidence that hemorrhage is not a direct effect of virus-induced cytolysis of endothelial cells. Am J Pathol 163 (2003) 2371-2382
152. Monath T.P., and Barrett A.D. Pathogenesis and pathophysiology of yellow fever. Adv Virus Res 60 (2003) 343-395
153. Pensiero M.N., Sharefkin J.B., Dieffenbach C.W., et al. Hantaan virus infection of human endothelial cells. J Virol 66 (1992) 5929-5936
154. Khaiboullina S.F., and St Jeor S.C. Hantavirus immunology. Viral Immunol 15 (2002) 609-625
155. Gallaher W.R., DiSimone C., and Buchmeier M.J. The viral transmembrane superfamily: possible divergence of Arenavirus and Filovirus glycoproteins from a common RNA virus ancestor. BMC Microbiol 1 (2001). http://www.biomedcentral.com/1471-2180/1/1
156. Takada A., Watanabe S., Ito H., et al. Downregulation of beta1 integrins by Ebola virus glycoprotein: implication for virus entry. Virology 278 (2000) 20-26
157. Takada A., Fujioka K., Tsuiji M., et al. Human macrophage C-type lectin specific for galactose and N-acetylgalactosamine promotes filovirus entry. J Virol 78 (2004) 2943-2947
158. Becker S., Spiess M., and Klenk H.D. The asialoglycoprotein receptor is a potential liver-specific receptor for Marburg virus. J Gen Virol 76 (1995) 393-399
159. Chan S.Y., Empig C.J., Welte F.J., et al. Folate receptor-alpha is a cofactor for cellular entry by Marburg and Ebola viruses. Cell 106 (2001) 117-126
160. Alvarez C.P., Lasala F., Carrillo J., et al. C-type lectins DC-SIGN and L-SIGN mediate cellular entry by Ebola virus in cis and in trans. J Virol 76 (2002) 6841-6844
161. Simmons G., Reeves J.D., Grogan C.C., et al. DC-SIGN and DC-SIGNR bind ebola glycoproteins and enhance infection of macrophages and endothelial cells. Virology 305 (2003) 115-123
162. Marzi A., Gramberg T., Simmons G., et al. DC-SIGN and DC-SIGNR interact with the glycoprotein of Marburg virus and the S protein of severe acute respiratory syndrome coronavirus. J Virol 78 (2004) 12090-12095
163. Gavrilovskaya I.N., Shepley M., Shaw R., et al. β3 integrins mediate the cellular entry of hantaviruses that cause respiratory failure. Proc Natl Acad Sci USA 95 (1998) 7074-7079
164. Cao W., Henry M.D., Borrow P., et al. Identification of α-dystroglycan as a receptor for lymphocytic choriomeningitis virus and Lassa fever virus. Science 282 (1998) 2079-2081
165. Spiropoulou C.F., Kunz S., Rollin P.E., et al. New World arenavirus clade C, but not clade A and B viruses, utilizes alpha-dystroglycan as its major receptor. J Virol 76 (2002) 5140-5146
166. Yang Z., Duckers H.J., Sullivan N.J., et al. Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury. Nat Med 6 (2000) 886-889
167. Lukashevich I.S., Maryankova R., Vladyko A.S., et al. Lassa and Mopeia virus replication in human monocytes/macrophages and in endothelial cells: different effects on IL-8 and TNF-alpha gene expression. J Med Virol 59 (1999) 552-560
168. Elsner B., Schwarz E., Mando O.G., et al. Pathology of 12 fatal cases of Argentine hemorrhagic fever. Am J Trop Med Hyg 22 (1973) 229-236
169. Terrell T.G., Stookey J.L., Eddy G.A., and Kastello M.D. Pathology of Bolivian hemorrhagic fever in the rhesus monkey. Am J Pathol 73 (1973) 477-494
170. Walker D.H., and Murphy F.A. Pathology and pathogenesis of arenavirus infections. Curr Top Microbiol Immunol 133 (1987) 89-113
171. Gear J.S., Cassel G.A., Gear A.J., et al. Outbreak of Marburg virus disease in Johannesburg. BMJ 4 (1975) 489-493
172. Murphy F.A. Pathology of Ebola virus infection. In: Pattyn S.R. (Ed). Ebola Virus Haemorrhagic Fever (1978), Elsevier/North-Holland Biomedical Press, New York 43-59
173. Feldmann H., Bugany H., Mahner F., et al. Filovirus-induced endothelial leakage triggered by infected monocytes/macrophages. J Virol 70 (1996) 2208-2214
174. Child P.L., MacKenzie R.B., Valverde L.R., and Johnson K.M. Bolivian hemorrhagic fever: a pathological description. Arch Path 83 (1967) 434-445
175. Gedigk P., Bechtelsheimer H., and Korb G. Pathologic anatomy of the Marburg virus disease. In: Martini G.A., and Siegert R. (Eds). Marburg Virus Disease (1971), Springer-Verlag, New York 50-53
176. Winn Jr. W.C., and Walker D.H. The pathology of human Lassa fever. Bull World Health Organ 52 (1975) 535-545
177. Walker D.H., McCormick J.B., Johnson K.M., et al. Pathologic and virologic study of fatal Lassa fever in man. Am J Pathol 107 (1982) 349-356
178. Green D.E., Mahlandt B.G., and McKee Jr. K.T. Experimental Argentine hemorrhagic fever in rhesus macaques: virus-specific variations in pathology. J Med Virol 22 (1987) 113-133
179. Elton N.W., Romero A., and Trejos A. Clinical pathology of yellow fever. Am J Clin Pathol 25 (1955) 135-146
180. Joubert J.R., King J.B., Rossouw D.J., et al. A nosocomial outbreak of Crimean-Congo haemorrhagic fever at Tygerberg Hospital. Part III. Clinical pathology and pathogenesis. S Afr Med J 68 (1985) 722-728
181. Peters C.J., Jahrling P.B., Liu C.T., et al. Experimental studies of arenaviral hemorrhagic fevers. Curr Top Microbiol Immunol 134 (1987) 5-68
182. Fisher-Hoch S.P., McCormick J.B., Sasso D., et al. Hematologic dysfunction in Lassa fever. J Med Virol 26 (1988) 127-135
183. Peters C.J., Jones D., Trotter R., et al. Experimental Rift Valley fever in rhesus macaques. Arch Virol 99 (1988) 31-44
184. Swanepoel R., Gill D.E., Shepherd A.J., et al. The clinical pathology of Crimean-Congo hemorrhagic fever. Rev Infect Dis 11 Suppl 4 (1989) S794-S800
185. Morrill J.C., Jennings G.B., Johnson A.J., et al. Pathogenesis of Rift Valley fever in rhesus monkeys: role of the interferon response. Arch Virol 110 (1990) 195-212
186. Fisher-Hoch S.P., Brammer T.L., Trappier S.G., et al. Pathogenic potential of filoviruses: role of geographic origin of primate host and virus strain. J Infect Dis 166 (1992) 753-763
187. McCormick J.B., Mitchell S.W., Kiley M.P., et al. Inactivated Lassa virus elicits a non protective immune response in rhesus monkeys. J Med Virol 37 (1992) 1-7
188. Elisaf M., Stefanaki S., Repanti M., et al. Liver involvement in hemorrhagic fever with renal syndrome. J Clin Gastroenterol 17 (1993) 33-37
189. Callis R.T., Jahrling P.B., and DePaoli A. Pathology of Lassa virus infection in the rhesus monkey. Am J Trop Med Hyg 31 (1982) 1038-1045
190. Frame J.D. Clinical features of Lassa fever in Liberia. Rev Infect Dis 11 Suppl 4 (1989) S783-S789
191. McLeod Jr. C.G., Stookey J.L., White J.D., et al. Pathology of Bolivian Hemorrhagic fever in the African green monkey. Am J Trop Med Hyg 27 (1978) 822-826
192. Cosgriff T.M. Mechanisms of disease in Hantavirus infection: pathophysiology of hemorrhagic fever with renal syndrome. Rev Infect Dis 13 (1991) 97-107
193. Duchin J.S., Koster F.T., Peters C.J., et al. Hantavirus pulmonary syndrome: a clinical description of 17 patients with a newly recognized disease. The Hantavirus Study Group. N Engl J Med 330 (1994) 949-955
194. Peters C.J. Arenaviruses. In: Richman D.D., Whitley R.J., and Hayden F.G. (Eds). Clincal Virology (1997), Churchill Livingstone, New York 973-996
195. Fisher-Hoch S.P., Mitchell S.W., Sasso D.R., et al. Physiological and immunologic disturbances associated with shock in a primate model of Lassa fever. J Infect Dis 155 (1987) 465-474
196. Hudson N. The pathology of experimental yellow fever in the Macaca rhesus. III. Comparison with the pathology of yellow fever in man. Am J Pathol 4 (1928) 419-439
197. Klotz O., and Belt T.H. Pathology in spleen in yellow fever. Am J Pathol 6 (1930) 655-662
198. Zlotnik I. Marburg agent disease: Pathology. Trans R Soc Trop Med Hyg 63 (1969) 310-323
199. Murphy F.A., Simpson D.I.H., Whitfield S.G., et al. Marburg virus infection in monkeys. Lab Invest 24 (1971) 279-291
200. Edington G.M., and White H.A. The pathology of Lassa fever. Trans R Soc Trop Med Hyg 66 (1972) 381-389
201. Monath T.P., Brinker K.R., Chandler F.W., et al. Pathophysiologic correlations in a rhesus monkey model of yellow fever with special observations on the acute necrosis of B cell areas of lymphoid tissues. Am J Trop Med Hyg 30 (1981) 431-443
202. Baskerville A., Satti A., Murphy F.A., et al. Congo-Crimean haemorrhagic fever in Dubai: histopathological studies. J Clin Pathol 34 (1981) 871-874
203. Fisher-Hoch S.P., Platt G.S., Lloyd G., et al. Haematological and biochemical monitoring of Ebola infection in rhesus monkeys: implications for patient management. Lancet 2 (1983) 1055-1058
204. Fisher-Hoch S.P., Platt G.S., Neild G.H., et al. Pathophysiology of shock and hemorrhage in a fulminating viral infection (Ebola). J Infect Dis 152 (1985) 887-894
205. McKee Jr. K.T., Mahlandt B.G., Maiztegui J.I., et al. Virus-specific factors in Argentine hemorrhagic fever in rhesus macaques. J Med Virol 22 (1987) 99-111
206. Simpson D.I.H. Marburg agent disease: in monkeys. Trans R Soc Trop Med Hyg 63 (1969) 303-309
207. Havemann K., and Schmidt H.A. Haematological findings in Marburg virus disease: evidence for involvement of the immunological system. In: Martini G.A., and Siegert R. (Eds). Marburg Virus Disease (1971), Springer-Verlag, New York 34-40
208. Kastello M.D., Eddy G.A., and Kuehne R.W. A rhesus monkey model for the study of Bolivian hemorrhagic fever. J Infect Dis 133 (1976) 57-62
209. Wagner F.S., Eddy G.A., and Brand O.M. The African green monkey as an alternate primate host for studying Machupo virus infection. Am J Trop Med Hyg 26 (1977) 159-162
210. Fisher-Hoch S.P., McCormick J.B., Auperin D., et al. Protection of rhesus monkeys from fatal Lassa fever by vaccination with a recombinant vaccinia virus containing the Lassa virus glycoprotein gene. Proc Natl Acad Sci USA 86 (1989) 317-321
211. Vallejos D.A., Ambrosio A.M., Feuillade M.R., et al. Lymphocyte subsets alteration in patients with Argentine hemorrhagic fever. J Med Virol 27 (1989) 160-163
212. Sanchez A., Lukwiya M., Bausch D., et al. Analysis of human peripheral blood samples from fatal and nonfatal cases of Ebola (Sudan) hemorrhagic fever: cellular responses, virus load, and nitric oxide levels. J Virol 78 (2004) 10370-10377
213. Baize S., Leroy E.M., Georges-Courbot M.C., et al. Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients. Nat Med 5 (1999) 423-426
214. Geisbert T.W., Hensley L.E., Gibb T.R., et al. Apoptosis induced in vitro and in vivo during infection by Ebola and Marburg viruses. Lab Invest 80 (2000) 171-186
215. Reed D.S., Hensley L.E., Geisbert J.B., et al. Depletion of peripheral blood T lymphocytes and NK cells during the course of Ebola hemorrhagic fever in cynomolgus macaques. Viral Immunol 17 (2004) 390-400
216. Hensley L.E., Young H.A., Jahrling P.B., et al. Proinflammatory response during Ebola virus infection of primate models: possible involvement of the tumor necrosis factor receptor superfamily. Immunol Lett 80 (2002) 169-179
217. Mahanty S., Hutchinson K., Agarwal S., et al. Cutting edge: impairment of dendritic cells and adaptive immunity by Ebola and Lassa viruses. J Immunol 170 (2003) 2797-2801
218. Baize S., Kaplon J., Faure C., et al. Lassa virus infection of human dendritic cells and macrophages is productive but fails to activate cells. J Immunol 172 (2004) 2861-2869
219. Baize S., Leroy E.M., Georges A.J., et al. Inflammatory responses in Ebola virus-infected patients. Clin Exp Immunol 128 (2002) 163-168
220. Calandra T., Gerain J., Heumann D., et al. High circulating levels of interleukin-6 in patients with septic shock: evolution during sepsis, prognostic value, and interplay with other cytokines. The Swiss-Dutch J5 Immunoglobulin Study Group. Am J Med 91 (1991) 23-29
221. Damas P., Ledoux D., Nys M., et al. Cytokine serum level during severe sepsis in human IL-6 as a marker of severity. Ann Surg 215 (1992) 356-362
222. Marty C., Misset B., Tamion F., et al. Circulating interleukin-8 concentrations in patients with multiple organ failure of septic and nonseptic origin. Crit Care Med 22 (1994) 673-679
223. Levis S.C., Saavedra M.C., Ceccoli C., et al. Endogenous interferon in Argentine hemorrhagic fever. J Infect Dis 149 (1984) 428-433
224. Levis S.C., Saavedra M.C., Ceccoli C., et al. Correlation between endogenous interferon and the clinical evolution of patients with Argentine hemorrhagic fever. J Interferon Res 5 (1985) 383-389
225. Heller M.V., Saavedra M.C., Falcoff R., et al. Increased tumor necrosis factor-alpha levels in Argentine hemorrhagic fever. J Infect Dis 166 (1992) 1203-1204
226. Groeneveld P.H., Colson P., Kwappenberg K.M., et al. Increased production of nitric oxide in patients infected with the European variant of hantavirus. Scand J Infect Dis 27 (1995) 453-456
227. Krakauer T., Leduc J.W., and Krakauer H. Serum levels of tumor necrosis factor-alpha, interleukin-1, and interleukin-6 in hemorrhagic fever with renal syndrome. Viral Immunol 8 (1995) 75-99
228. Marta R.F., Montero V.S., Hack C.E., et al. Proinflammatory cytokines and elastase-α-1-antitrypsin in Argentine hemorrhagic fever. Am J Trop Med Hyg 60 (1999) 85-89
229. Mori M., Rothman A.L., Kurane I., et al. High levels of cytokine-producing cells in the lung tissues of patients with fatal hantavirus pulmonary syndrome. J Infect Dis 179 (1999) 295-302
230. Villinger F., Rollin P.E., Brar S.S., et al. Markedly elevated levels of interferon (IFN)-gamma, IFN-alpha, interleukin (IL)-2, IL-10, and tumor necrosis factor-alpha associated with fatal Ebola virus infection. J Infect Dis 179 Suppl 1 (1999) S188-S191
231. Ignatiev G.M., Dadaeva A.A., Luchko S.V., et al. Immune and pathophysiological processes in baboons experimentally infected with Ebola virus adapted to guinea pigs. Immunol Lett 71 (2000) 131-140
232. Mahanty S., Bausch D.G., Thomas R.L., et al. Low levels of interleukin-8 and interferon-inducible protein-10 in serum are associated with fatal infections in acute Lassa fever. J Infect Dis 183 (2001) 1713-1721
233. Davis I.C., Zajac A.J., Nolte K.B., et al. Elevated generation of reactive oxygen/nitrogen species in hantavirus cardiopulmonary syndrome. J Virol 76 (2002) 8347-8359
234. ter Meulen J., Sakho M., Koulemou K., et al. Activation of the cytokine network and unfavorable outcome in patients with yellow fever. J Infect Dis 190 (2004) 1821-1827
235. Ergonul O., Tuncbilek S., Baykam N., et al. Evaluation of serum levels of interleukin (IL)-6, IL-10, and tumor necrosis factor-alpha in patients with Crimean-Congo hemorrhagic fever. J Infect Dis 193 (2006) 941-944
236. Stroher U., West E., Bugany H., et al. Infection and activation of monocytes by Marburg and Ebola viruses. J Virol 75 (2001) 11025-11033
237. Sundstrom J.B., McMullan L.K., Spiropoulou C.F., et al. Hantavirus infection induces the expression of RANTES and IP-10 without causing increased permeability in human lung microvascular endothelial cells. J Virol 75 (2001) 6070-6085
238. Gomez R.M., Pozner R.G., Lazzari M.A., et al. Endothelial cell function alteration after Junin virus infection. Thromb Haemost 90 (2003) 326-333
239. Leroy E.M., Baize S., Volchkov V.E., et al. Human asymptomatic Ebola infection and strong inflammatory response. Lancet 355 (2000) 2210-2215
240. Li H., and Forstermann U. Nitric oxide in the pathogenesis of vascular disease. J Pathol 190 (2000) 244-254
241. Peters C.J., Liu C.T., Anderson Jr. G.W., et al. Pathogenesis of viral hemorrhagic fevers: Rift Valley fever and Lassa fever contrasted. Rev Infect Dis 11 Suppl 4 (1989) S743-S749
242. Asper M., Sternsdorf T., Hass M., et al. Inhibition of different Lassa virus strains by alpha and gamma interferons and comparison with a less pathogenic arenavirus. J Virol 78 (2004) 3162-3169
243. Foster G.R., and Finter N.B. Are all type I human interferons equivalent?. J Viral Hepat 5 (1998) 143-152
244. Basler C.F., Wang X., Muhlberger E., et al. The Ebola virus VP35 protein functions as a type I IFN antagonist. Proc Natl Acad Sci USA 97 (2000) 12289-12294
245. Basler C.F., Mikulasova A., Martinez-Sobrido L., et al. The Ebola virus VP35 protein inhibits activation of interferon regulatory factor 3. J Virol 77 (2003) 7945-7956
246. Basler C.F., and Palese P. Modulation of innate immunity by filoviruses. In: Klenk H.D., and Feldmann H. (Eds). Ebola and Marburg viruses: molecular and cellular biology (2004), Horizon Bioscience, Norfolk, UK 305-349
247. Bouloy M., Janzen C., Vialat P., et al. Genetic evidence for an interferon-antagonist function of rift valley fever virus nonstructural protein NSs. J Virol 75 (2001) 1371-1377
248. Martini G.A., Knauff H.G., Schmidt H.A., et al. A hitherto unknown infectious disease contracted from monkeys. "Marburg-virus" disease. Ger Med Mon 13 (1968) 457-470
249. Bwaka M.A., Bonnet M.J., Calain P., et al. Ebola hemorrhagic fever in Kikwit, Democratic Republic of the Congo: clinical observations in 103 patients. J Infect Dis 179 Suppl 1 (1999) S1-S7
250. Bowen E.T., Platt G.S., Simpson D.I., et al. Ebola haemorrhagic fever: experimental infection of monkeys. Trans R Soc Trop Med Hyg 72 (1978) 188-191
251. Geisbert T.W., Hensley L.E., Jahrling P.B., et al. Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys. Lancet 362 (2003) 1953-1958
252. Mackenzie R.B., Beye H.K., Valverde L., et al. Epidemic hemorrhagic fever in Bolivia. I. A preliminary report of the epidemiological and clinical findings in a new epidemic area in South America. Am J Trop Med Hyg 13 (1964) 620-625
253. Peters C.J., Zaki S.R., and Rollin P.E. Viral hemorrhagic fevers. In: Feteky R. (Ed). Atlas of Infectious Diseases (1997), Churchill Livingstone, Philadelphia 10.1-10.26
254. Molinas F.C., de Bracco M.M., and Maiztegui J.I. Coagulation studies in Argentine hemorrhagic fever. J Infect Dis 143 (1981) 1-6
255. Dennis L.H., Reisberg B.E., Crosbie J., et al. The original haemorrhagic fever: yellow fever. Br J Haematol 17 (1969) 455-462
256. Scott S.K., Hickman R.L., Lang C.M., et al. Studies of the coagulation system and blood pressure during experimental Bolivian hemorrhagic fever in rhesus monkeys. Am J Trop Med Hyg 27 (1978) 1232-1239
257. Molinas F.C., Giavedoni E., Frigerio M.J., et al. Alteration of blood coagulation and complement system in neotropical primates infected with Junin virus. J Med Virol 12 (1983) 281-292
258. Heller M.V., Marta R.F., Sturk A., et al. Early markers of blood coagulation and fibrinolysis activation in Argentine hemorrhagic fever. Thromb Haemost 73 (1995) 368-373
259. Courouble P., Vanpee D., Delgrange E., et al. Hantavirus infections: clinical presentation in the emergency room. Eur J Emerg Med 8 (2001) 17-20
260. Geisbert T.W., Young H.A., Jahrling P.B., et al. Mechanisms underlying coagulation abnormalities in Ebola hemorrhagic fever: overexpression of tissue factor in primate monocytes/macrophages is a key event. J Infect Dis 188 (2003) 1618-1629
261. Knobloch J., McCormick J.B., Webb P.A., et al. Clinical obersvations in 42 patients with Lassa fever. Tropenmed Parasitol 31 (1980) 389-398
262. Lange J.V., Mitchell S.W., McCormick J.B., et al. Kinetic study of platelets and fibrinogen in Lassa virus-infected monkeys and early pathologic events in Mopeia virus-infected monkeys. Am J Trop Med Hyg 34 (1985) 999-1007
263. Mammen E.F. Disseminated intravascular coagulation (DIC). Clin Lab Sci 13 (2000) 239-245
264. Levi M. Current understanding of disseminated intravascular coagulation. Br J Haematol 124 (2004) 567-576
265. Rippey J.J., Schepers N.J., and Gear J.H. The pathology of Marburg virus disease. S Afr Med J 66 (1984) 50-54
266. Isaacson M., Sureua P., Courtielle G., et al. Clinical aspects of Ebola virus disease at the Ngaliema hospital, Kinshasa, Zaire, 1976. In: Pattyn S.R. (Ed). Ebola Virus Haemorrhagic Fever (1978), Elsevier/North-Holland Biomedical Press, New York 15-20
267. Lee M., Lee J.S., and Kim B.K. Disseminated intravascular coagulation in Korean hemorrhagic fever. Bibl Haematol 49 (1983) 181-199
268. Nolte K.B., Feddersen R.M., Foucar K., et al. Hantavirus pulmonary syndrome in the United States: a pathological description of a disease caused by a new agent. Hum Pathol 26 (1995) 110-120
269. Santos F., Pereira L.C., Paiva M., et al. Coagulacao intravascular diseminada aguda na febre amarela: dosagem dos factores da coagulacao. Brasilia Med 9 (1973) 9-16
270. Grignani G., and Maiolo A. Cytokines and hemostasis. Haematologica 85 (2000) 967-972
271. Neumann F.-J., Ott I., Marx N., et al. Effect of human recombinant interleukin-6 and interleukin-8 on monocyte procoagulant activity. Arterioscler Thromb Vasc Biol 17 (1997) 3399-3405
272. Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiology and Biomedical Laboratories (1999), Government Printing Office, Washington, DC. http://www.cdc.gov/od/ohs/pdffiles/4th%20BMBL.pdf . Accessed June 4, 2006
273. van der Groen G., and Elliot L.H. Use of betapropiolactone inactivated Ebola, Marburg and Lassa intracellular antigens in immunofluorescent antibody assay. Ann Soc Belg Med Trop 62 (1982) 49-54
274. Trappier S.G., Contay A.L., Farrar B.B., et al. Evaluation for the polymerase chain reaction for diagnosis of Lassa virus infection. Am J Trop Med Hyg 49 (1993) 214-221
275. Leroy E.M., Baize S., Lu C.Y., et al. Diagnosis of Ebola hemorrhagic fever by RT-PCR in an epidemic setting. J Med Virol 60 (2000) 463-467
276. Drosten C., Gottig S., Schilling S., et al. Rapid detection and quantification of RNA of Ebola and Marburg viruses, Lassa virus, Crimean-Congo hemorrhagic fever virus, Rift Valley fever virus, dengue virus, and yellow fever virus by real-time reverse transcription-PCR. J Clin Microbiol 40 (2002) 2323-2330
277. Towner J.S., Rollin P.E., Bausch D.G., et al. Rapid diagnosis of Ebola hemorrhagic fever by reverse transcription-PCR in an outbreak setting and assessment of patient viral load as a predictor of outcome. J Virol 78 (2004) 4330-4341
278. Geisbert T.W., Rhoderick J.B., and Jahrling P.B. Rapid identification of Ebola and related filoviruses in fluid specimens by indirect immunoelectron microscopy. J Clin Pathol 44 (1991) 521-522
279. Geisbert T.W., and Jahrling P.B. Differentiation of filoviruses by electron microscopy. Virus Res 39 (1995) 129-150
280. Zaki S.R., Shieh W.J., Greer P.W., et al. A novel immunohistochemical assay for the detection of Ebola virus in skin: implications for diagnosis, spread, and surveillance of Ebola hemorrhagic fever. Commission de Lutte contre les Epidemies a Kikwit. J Infect Dis 179 Suppl 1 (1999) S36-S47
281. Schnittler H.J., and Feldmann H. Viral hemorrhagic fever-a vascular disease?. Thromb Haemost 89 (2003) 967-972
282. Geisbert T.W., Marty A.M., and Jahrling P.B. Viral Hemorrhagic Fevers. In: Roy M.J. (Ed). Physician's Guide to Terrorist Attack (2004), Humana Press, Totowa, NJ 221-242
283. Geisbert T.W., and Jahrling P.B. Exotic emerging viral diseases: progress and challenges. Nat Med 10 12 Suppl (2004) S110-S121